ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Preliminary data demonstrate that irAEs induced by immune checkpoint blockade can be
successfully treated with ECP (Apostolova et al. NEJM 2020). Therefore this clinical phase
1/2 trial is launched to validate the finding made with the individual patient in a
prospective trial. The primary objective is evaluation of safety of ECP treatment in patients
with irAEs. As a secondary objective, the study will determine the efficacy of ECP as a
treatment for immune-related adverse events and its effect on tumor progression.